The use of infliximab in cutaneous sarcoidosis.

Infliximab, a chimeric (humanized mouse) monoclonal antibody which specifically inhibits TNF-alpha, has recently shown efficacy in the treatment of refractory sarcoidosis. The manifestations of sarcoidosis are diverse; however, the long-term effects on the lungs are often the most life-threatening. We describe a patient with sarcoidosis who experienced the complete resolution of her cutaneous disease and stabilization of her pulmonary symptoms after initiation of infliximab.